Severe persistent visual field constriction associated with vigabatrin. Manufacturers have started several studies.
作者信息
Backstrom J T, Hinkle R L, Flicker M R
出版信息
BMJ. 1997 Jun 7;314(7095):1694-5.
Abstract
摘要
相似文献
1
Severe persistent visual field constriction associated with vigabatrin. Manufacturers have started several studies.
BMJ. 1997 Jun 7;314(7095):1694-5.
2
3
4
Severe persistent visual field constriction associated with vigabatrin. Four possible explanations exist.
BMJ. 1997 Jun 7;314(7095):1694.
5
6
Severe persistent visual field constriction associated with vigabatrin. Reaction might be dose dependent.
BMJ. 1997 Jun 7;314(7095):1693-4.
7
8
Infantile spasms and vigabatrin. Visual field defects may be permanent.
BMJ. 1999 Jan 2;318(7175):57.
9
Symptomatic and asymptomatic visual loss in patients taking vigabatrin.
Ophthalmology. 1999 Sep;106(9):1792-8. doi: 10.1016/S0161-6420(99)90345-7.
10
Severe persistent visual field constriction associated with vigabatrin.
BMJ. 1997 Jan 18;314(7075):180-1. doi: 10.1136/bmj.314.7075.180.
引用本文的文献
1
Dose-related changes in retinal function and PKC-alpha expression in rabbits on vigabatrin medication. Effect of vigabatrin in the rabbit eye.
Graefes Arch Clin Exp Ophthalmol. 2009 Aug;247(8):1057-67. doi: 10.1007/s00417-009-1093-7. Epub 2009 May 3.
2
Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy.
Doc Ophthalmol. 2008 Sep;117(2):93-101. doi: 10.1007/s10633-007-9108-3. Epub 2008 Jan 10.
3
Retinal function in rabbits does not improve 4-5 months after terminating treatment with vigabatrin.
Doc Ophthalmol. 2006 Jan;112(1):35-41. doi: 10.1007/s10633-006-0004-z.
4
Alterations in electroretinograms and retinal morphology in rabbits treated with vigabatrin.
Doc Ophthalmol. 2004 Mar;108(2):125-33. doi: 10.1023/b:doop.0000036780.96560.74.
5
Visual field constriction and electrophysiological changes associated with vigabatrin.
Doc Ophthalmol. 2002 Mar;104(2):151-70. doi: 10.1023/a:1014644307518.
6
Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication.
Doc Ophthalmol. 2001 Jan;102(1):63-72. doi: 10.1023/a:1017589301855.
7
Visual field defects with vigabatrin: epidemiology and therapeutic implications.
CNS Drugs. 2001;15(3):217-30. doi: 10.2165/00023210-200115030-00005.
Zotero 插件